According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
2024 full-year revenue guidance raised by US$ 2 billion
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Glenmark’s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics, USA
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Sales reflect continued strong growth in oncology and vaccines
Subscribe To Our Newsletter & Stay Updated
